JP7082258B2 - うっ血性心不全に罹っている対象を治療するためのリボースの使用 - Google Patents

うっ血性心不全に罹っている対象を治療するためのリボースの使用 Download PDF

Info

Publication number
JP7082258B2
JP7082258B2 JP2018540107A JP2018540107A JP7082258B2 JP 7082258 B2 JP7082258 B2 JP 7082258B2 JP 2018540107 A JP2018540107 A JP 2018540107A JP 2018540107 A JP2018540107 A JP 2018540107A JP 7082258 B2 JP7082258 B2 JP 7082258B2
Authority
JP
Japan
Prior art keywords
agent
ribose
subject
administration
decrease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018540107A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019504085A5 (enExample
JP2019504085A (ja
Inventor
エー．トンプソン ジェフリー
ハンカリ ラージ
Original Assignee
バイオエナジー ライフ サイエンス，インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイオエナジー ライフ サイエンス，インコーポレイティド filed Critical バイオエナジー ライフ サイエンス，インコーポレイティド
Publication of JP2019504085A publication Critical patent/JP2019504085A/ja
Publication of JP2019504085A5 publication Critical patent/JP2019504085A5/ja
Application granted granted Critical
Publication of JP7082258B2 publication Critical patent/JP7082258B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2018540107A 2016-02-01 2017-01-19 うっ血性心不全に罹っている対象を治療するためのリボースの使用 Active JP7082258B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662289562P 2016-02-01 2016-02-01
US62/289,562 2016-02-01
PCT/US2017/014034 WO2017136143A1 (en) 2016-02-01 2017-01-19 Use of ribose for treatment of subjects having congestive heart failure

Publications (3)

Publication Number Publication Date
JP2019504085A JP2019504085A (ja) 2019-02-14
JP2019504085A5 JP2019504085A5 (enExample) 2020-02-27
JP7082258B2 true JP7082258B2 (ja) 2022-06-08

Family

ID=57915160

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018540107A Active JP7082258B2 (ja) 2016-02-01 2017-01-19 うっ血性心不全に罹っている対象を治療するためのリボースの使用

Country Status (4)

Country Link
US (1) US10821123B2 (enExample)
EP (2) EP3411041A1 (enExample)
JP (1) JP7082258B2 (enExample)
WO (1) WO2017136143A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114209709A (zh) * 2021-12-16 2022-03-22 海门品尚医药科技有限公司 D-核糖在制备改善药物性心脏毒性药物或食品中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100009924A1 (en) 2000-07-28 2010-01-14 Bioenergy, Inc. Compositions and methods for improving cardiovascular function
US20110053869A1 (en) 2008-01-25 2011-03-03 Foker John E Methods and compositions for inhibiting progression to chronic cardiac failure

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4605644A (en) 1985-02-07 1986-08-12 Regents Of The University Of Minnesota Method for stimulating recovery from ischemia employing ribose and adenine
US4719201A (en) 1985-02-07 1988-01-12 Regents Of The University Of Minnesota Method for stimulating recovery from ischemia
US4824660A (en) 1985-06-06 1989-04-25 Paul S. Angello Method of determining the viability of tissue in an organism
US4920098A (en) 1986-09-17 1990-04-24 Baxter International Inc. Nutritional support or therapy for individuals at risk or under treatment for atherosclerotic vascular, cardiovascular, and/or thrombotic diseases
AU2228888A (en) 1987-10-14 1989-05-25 Takeda Chemical Industries Ltd. Aqueous pharmaceutical preparation for oral administration
US4871718A (en) 1987-12-29 1989-10-03 Raymond A. Roncari Composition of matter for increasing intracellular ATP levels and physical performance levels and for increasing the rate of wound repair
US5658889A (en) * 1989-01-24 1997-08-19 Gensia Pharmaceuticals, Inc. Method and compounds for aica riboside delivery and for lowering blood glucose
US4968719A (en) 1989-04-03 1990-11-06 Sigma Tau, Industrie Farmaceutiche Riunite Spa Method for treating vascular disease
JPH02286620A (ja) 1989-04-27 1990-11-26 Riide Chem Kk 抗高脂血症用剤
EP0441119A3 (en) 1990-01-09 1992-10-14 Richard D. Levere The use of l-arginine in the treatment of hypertension and other vascular disorders
US5114723A (en) 1990-02-27 1992-05-19 University Of Texas System Board Of Regents Beverage compositions for human consumption
IT1247125B (it) 1991-03-01 1994-12-12 Depha Team Srl Composizioni dietetiche o farmaceutiche per il ripristino del contenuto cellulare degli adenin nucleotidi nel muscolo scheletrico e cardiaco.
US5292538A (en) 1992-07-22 1994-03-08 Metagenics, Inc. Improved sustained energy and anabolic composition and method of making
GB9215746D0 (en) 1992-07-24 1992-09-09 Hultman Eric A method of increasing creatine supply depot
DE4228215A1 (de) 1992-08-25 1994-03-03 Pliml Wolfgang Verwendung von Ribose zur Herstellung eines Arzneimittels zur Behandlung von Leistungsschwächen des Körpers, insbesondere von Organinsuffizienzen
ES2196053T3 (es) 1994-01-11 2003-12-16 Stichting Zofia Procedimiento para el tratamiento de trastornos del cuerpo humano o animal mediante la administracion de aminoacidos.
AU1780395A (en) 1994-05-02 1995-11-09 Omeara (Proprietary) Limited Amino acid, carnitine and magnesium supplementation
US5536751A (en) 1994-05-09 1996-07-16 The United States Of America As Represented By The Secretary Of The Army Pharmaceutical alpha-keto carboxylic acid compositions method of making and use thereof
GB9517443D0 (en) 1994-12-17 1995-10-25 Univ Nottingham Increasing creatine and glycogen concentration in muscle
US5707971A (en) 1995-06-07 1998-01-13 Life Resuscitation Technologies, Inc. Modulation of glycolytic ATP production
US5804596A (en) 1997-02-27 1998-09-08 Sabinsa Corporation Method of preparing a forskohlin composition from forskohlin extract and use of forskohlin for promoting lean body mass and treating mood disorders
US6054128A (en) 1997-09-29 2000-04-25 Wakat; Diane Dietary supplements for the cardiovascular system
US6218366B1 (en) 1998-06-19 2001-04-17 Bioenergy, Inc. Method for raising the hypoxic threshold
US6159942A (en) 1998-06-19 2000-12-12 Bioenergy, Inc. Compositions for increasing energy in vivo
US6051236A (en) 1998-11-12 2000-04-18 Pacifichealth Laboratories, Inc. Composition for optimizing muscle performance during exercise
US6429198B1 (en) 1999-04-12 2002-08-06 Bioenergy Inc. Compositions for increasing athletic performance in mammals
US6534480B2 (en) 1999-06-17 2003-03-18 Bioenergy Inc. Compositions for increasing energy in vivo
US6511964B2 (en) 1999-09-24 2003-01-28 Bioenergy, Inc. Method for treating acute mountain sickness
US6339716B1 (en) 1999-09-24 2002-01-15 Bioenergy Inc. Method for determining viability of a myocardial segment
US6159943A (en) 1999-09-24 2000-12-12 Bioenergy, Inc. Use of ribose to prevent cramping and soreness in muscles
US6172114B1 (en) 1999-09-30 2001-01-09 Worldwide Sports Nutritional Supplements, Inc. Creatine supplement
US6703370B1 (en) 1999-10-27 2004-03-09 Bioenergy, Inc. Use of ribose to treat fibromyalgia
US6663859B2 (en) 2000-01-07 2003-12-16 Bioenergy, Inc. Compositions for enhancing the immune response
US6525027B2 (en) 2000-01-20 2003-02-25 Bioenergy Inc. Use of ribose supplementation for increasing muscle mass and decreasing body fat in humans
US6420342B1 (en) 2000-05-08 2002-07-16 N.V. Nutricia Nutritional preparation comprising ribose and medical use thereof
US20030212006A1 (en) 2002-05-13 2003-11-13 Seifert John G. Method for reducing free radical formation in healthy individuals undergoing hypoxic exercise and medical conditions with increased oxygen free radicals
US20090197818A1 (en) 2004-01-14 2009-08-06 St Cyr John A Use Of Ribose for Recovery From Anaesthesia
US20050277598A1 (en) 2004-04-29 2005-12-15 Maccarter Dean J Method for improving ventilatory efficiency
US20100099630A1 (en) 2004-04-29 2010-04-22 Maccarter Dean J Method for improving ventilatory efficiency
US8835396B2 (en) 2006-12-15 2014-09-16 Bioenergy, Inc. Method and compositions for improving pulmonary hypertension
US8101581B2 (en) 2007-01-23 2012-01-24 Bioenergy, Inc. Use of D-ribose to treat cardiac arrhythmias
WO2009123742A1 (en) 2008-04-02 2009-10-08 St Cyr John A Use of ribose in first response to acute myocardial infarction
US20090286750A1 (en) 2008-05-16 2009-11-19 Kasubick Robert V Use of ribose in lessening the clinical symptoms of aberrant firing of neurons

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100009924A1 (en) 2000-07-28 2010-01-14 Bioenergy, Inc. Compositions and methods for improving cardiovascular function
US20110053869A1 (en) 2008-01-25 2011-03-03 Foker John E Methods and compositions for inhibiting progression to chronic cardiac failure

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JEFF THOMPSON，EVALUATION OF D-RIBOSE PHARMACOKINETICS, DOSE PROPORTIONALITY, FOOD EFFECT, AND 以下備考，JOURNAL OF CLINICAL PHARMACOLOGY，米国，2013年12月16日，VOL: 54, NR: 5，PAGE(S) 546 - 554，https://accp1.onlinelibrary.wiley.com/doi/pdf/10.1002/jcph.241，PHARMACODYNAMICS AFTER ORAL SOLUTION ADMINISTRATION IN HEALTHY MALE AND FEMALE SUBJECTS
MELIKE BAYRAM，D-RIBOSE AIDS HEART FAILURE PATIENTS WITH PRESERVED EJECTION FRACTION AND 以下備考，THERAPEUTIC ADVANCES IN CARDIOVASCULR DISEASE，2015年01月01日，VOL:9,NR:3，PAGE(S) 56 - 65，https://journals.sagepub.com/doi/10.1177/1753944715572752，DIASTOLIC DYSFUNCTION: A PILOT STUDY

Also Published As

Publication number Publication date
US20170216330A1 (en) 2017-08-03
EP4241838A2 (en) 2023-09-13
EP4241838A3 (en) 2023-12-20
US10821123B2 (en) 2020-11-03
EP3411041A1 (en) 2018-12-12
WO2017136143A1 (en) 2017-08-10
JP2019504085A (ja) 2019-02-14

Similar Documents

Publication Publication Date Title
Provotorov et al. Endothelio-and cardioprotective effects of vitamin В6 and folic acid in modelling methionine-induced hyperhomocysteinemia
Owecki et al. Acute myocardial infarction during high-dose methylprednisolone therapy for Graves’ ophthalmopathy
Waagstein et al. Clinical results with prenalterol in patients with heart failure
JP7082258B2 (ja) うっ血性心不全に罹っている対象を治療するためのリボースの使用
JP5087389B2 (ja) 慢性心不全を治療するためのペルヘキシリン
US20230111558A1 (en) Composition for Preventing and Treating Heart Dysfunction and its Application Thereof
Kenny The nuts and bolts of cardiac resynchronization therapy
WO2023005002A1 (zh) 枸橼酸爱地那非在制备预防和或治疗肺动脉高压的药物中的用途
JP2023522579A (ja) 繊維及びマルベリーを含む組成物
WO2020201263A1 (en) Methods and pharmaceutical compositions for the treatment and prevention of cardiac remodeling
JP2018135278A (ja) 循環器疾患及び／又はミトコンドリア病の改善用医薬
Conti et al. Calcium antagonists
HK40099981A (en) Use of ribose for treatment of subjects having congestive heart failure
JP5596779B2 (ja) 急性心筋梗塞に対する初期対応におけるリボースの使用
Heo et al. A case of dilated cardiomyopathy with massive left ventricular thrombus after use of a sibutramine-containing slimming product
CN113143941B (zh) 西红花苷ⅰ在制备治疗轻症免疫性心肌炎药物中的应用
Hokimoto et al. Atrioventricular nodal ablation and biventricular pacing therapy with coronary venoplasty for severe heart failure with drug refractory atrial tachycardia
Rudenko et al. Cardiometric study of the cardiovascular system performance under the influence of prolonged smoking and some other stresses
JP2019504085A5 (enExample)
Cleland et al. The selective cardiac myosin activator, CK-1827452, increases systolic function in heart failure
US20080070917A1 (en) Methods for administering levosimendan
Yesilyurt et al. The Effects of Low-Dose Empagliflozin on Cardiac Function and Β-Adrenoceptor Responses in a Rat Model of Streptozotocin-Induced Diabetes
Kiavar et al. Is there any positive remodeling after enhanced external counter pulsation in patients with severe refractory angina?
Nissen et al. Oral treatment of AV block and other bradycardias with sustained action isoprenaline
Diaz et al. Nesiritide for the treatment of diastolic dysfunction

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200120

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200120

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20201109

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201117

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210517

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211005

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20211104

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220415

R150 Certificate of patent or registration of utility model

Ref document number: 7082258

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250